Artificial Intelligence in Drug Discovery and Development: Transforming Modern Pharmaceutical Research

Abstract

Artificial intelligence (AI) has emerged as a transformative technology in drug discovery and development, offering new approaches for identifying therapeutic targets, designing molecules, predicting drug properties, optimizing lead compounds, and improving clinical-trial processes. Conventional drug development is often characterized by long timelines, substantial financial costs, high attrition rates, and extensive experimental requirements. AI and machine-learning techniques provide opportunities to analyze large and complex biological and chemical datasets and identify relationships that may not be readily apparent through traditional approaches. Deep learning, natural language processing, generative models, reinforcement learning, molecular simulation, and graph-based algorithms are increasingly being applied to target identification, virtual screening, de novo molecular design, drug repurposing, toxicity prediction, pharmacokinetic modelling, and biomarker discovery. Generative artificial intelligence is particularly promising because it can propose novel molecular structures according to predefined biological or physicochemical objectives. AI can also support clinical development by improving patient selection, identifying trial sites, predicting recruitment challenges, analyzing real-world evidence, and monitoring safety signals. Nevertheless, AI-driven pharmaceutical research faces substantial challenges involving data quality, dataset bias, limited biological understanding, model interpretability, reproducibility, intellectual property, regulatory uncertainty, and the need for experimental validation. A computationally promising molecule does not automatically become an effective medicine; laboratory, preclinical, and clinical evidence remain essential. The future of AI in drug development is therefore likely to depend on close integration between computational models and experimental science rather than replacement of conventional pharmaceutical research. This paper examines the applications, benefits, limitations, ethical issues, regulatory considerations, and future prospects of AI-enabled drug discovery and development. It argues that responsible integration of AI could increase the efficiency of pharmaceutical research while creating new opportunities for precision therapeutics and previously unexplored treatment strategies.